Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ONO-5129 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ONO-5129 | DRUG | - |
Inclusion Criteria: 1. Fasting Blood Glucose 126-250mg/dL 2. HbA1c 6.5-11% Exclusion Criteria: 1. Previous treatment with antidiabetic agents equal to or less than 2-3 months prior to randomization 2. History of myocardial infarction, coronary artery surgery 3. Other eligibility criteria as speci...
ONO-5129 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is a metabolic therapeutic that has been studied in a Phase 2 clinical trial. The drug is not yet approved and remains in clinical development.
ONO-5129 is being developed by BrainsWay Ltd., a company traded on the NASDAQ under the ticker symbol BWAY. The drug is currently in Phase 2 clinical development for Type 2 Diabetes Mellitus.
ONO-5129 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a pilot study in patients with Type 2 Diabetes Mellitus. The drug is investigational and has not been approved by regulatory authorities.
ONO-5129 has been studied in one completed Phase 2 clinical trial, identified as NCT00335712. This was a pilot study involving 81 patients with Type 2 Diabetes Mellitus in Japan. The trial was randomized and double-blind, though it did not use a control group.
ONO-5129 is a distinct investigational drug candidate. No alternative names for ONO-5129 have been disclosed in the clinical trial information. It is being developed specifically for Type 2 Diabetes Mellitus and is not known to be identical to any other marketed medication.